SEC Form 4 · accession 0001450324-17-000003
AIM ImmunoTech Inc. · AIM
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Thomas K. Equels
Officer — CEO / President · Director
Period of report
Jun 8, 2017
Accepted (ET)
Jun 9, 2017 · 11:55 am EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000946644
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Options to buy Common Stock | $0.56 | Jun 8, 2017 | J | 300,000 | A | Jun 8, 2017 | Jun 8, 2027 | Common Stock | 300,000 | 495,833 | D |
Explanation of responses
- F1Stock Options issued per the employment agreement.